Developer docs
API playgroundTry for free, no card

Search company profiles

Nephrolyx

Full company profile

uuid000hu9i

Namestring
Nephrolyx
Legal namestring
Nephrolyx GmbH
Websiteurl
nephrolyx.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Nephrolyx GmbH is a Berlin-based diagnostics company that develops measured Glomerular Filtration Rate (mGFR) testing solutions for kidney function assessment. Its core product, Nephrolyx IVDx, combines a CE-marked in vitro diagnostic (IVD) iohexol-based kit with a digital GFRx software module that integrates into customer Laboratory Information Management Systems (LIMS) and computes mGFR via pharmacokinetic algorithms from (U)HPLC measurement data. The company also offers DNPx, a digital nephrology platform for research use supporting both multi-sample and single-sample protocols. The underlying technology leverages 12 years of research conducted at Charité Universitätsmedizin Berlin and is positioned as a more accurate, cost-effective, and rapid (<6-hour turnaround) alternative to existing mGFR methods such as 99mTc-DTPA and lab-developed tests, as well as biomarker-based estimated GFR (eGFR) approaches.

The company serves clinical laboratories with UHPLC/HPLC capabilities, physicians and nephrologists, hospitals and ambulatory care settings, and pharma/biotech companies conducting kidney research and clinical trials. Revenue is generated through IVD kit sales, software licensing/subscription for the GFRx module and DNPx platform, and professional services or research-collaboration arrangements with pharmaceutical sponsors. Pricing is quote-based and not publicly disclosed; go-to-market is enterprise field sales supported by a 2-week demo trial, with primary marketing channels being the corporate website, LinkedIn, and earned media in German outlets such as Der Tagesspiegel and Adlershof news. Funding to date has come entirely from a non-dilutive ERDF/State of Brandenburg ProFIT grant (NephroAL project); no institutional venture equity is disclosed. Leadership is led by Managing Director Dr. Markus Riester, with operations across Berlin-Adlershof and Wildau, Germany.

Geographically, Nephrolyx is CE-marked for the European market and explicitly not available for clinical diagnostic use in the United States, with EMEA as the disclosed served market. The company has 1-10 employees and operates as an independent, founder-driven German private limited liability company.

Short descriptiontext

Nephrolyx GmbH is a Berlin-based diagnostics company that provides CE-marked Nephrolyx IVDx (iohexol IVD kit plus GFRx LIMS-integrated software) and the DNPx research platform for measured Glomerular Filtration Rate (mGFR) kidney function testing, serving clinical laboratories, physicians, hospitals, and pharma/biotech research customers across EMEA.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBerlin, Germany
HQ citystring
Berlin
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
kidney function diagnostics, glomerular filtration rate, iohexol plasma clearance, in vitro diagnostics, nephrology software platform
Industry1 code
PRIMARYHLAHAKAJ
Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Clinical Kidney Function Diagnostics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1IVD Kit Sales
TypeHardware Sales
Description

Sale of IVD kits for clinical kidney function diagnostics. Nephrolyx IVDx combines an IVD kit with a digital software module.

nephrolyx.com
2Software Licensing (GFRx/DNPx)
TypeSubscription Recurring
Description

Digital GFRx software module for clinical use integrated into LIMS systems, and DNPx digital platform for research use. Software modules likely sold through licensing or subscription model.

nephrolyx.com
3Pharma/Biotech Research Support
TypeProfessional Services
Description

Supporting pharma and biotech companies in kidney research and clinical trials, likely through service or licensing arrangements.

nephrolyx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1Enterprise/Laboratory pricing - quote-based
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing not publicly disclosed. Contact sales for demo trial and pricing information.

nephrolyx.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Nephrolyx develops and sells the Nephrolyx IVDx, a CE-marked in vitro diagnostic (IVD) kit combined with a digital GFRx software module for measuring Glomerular Filtration Rate (mGFR) using iohexol-plasma-clearance in clinical routine. The software integrates into laboratory LIMS systems and is designed for semi-automatic processing on UHPLC/HPLC devices. For research use, Nephrolyx offers the DNPx Digital Nephrology Platform, which calculates mGFR via pharmacokinetic algorithms from iohexol concentrations obtained through (U)HPLC measurements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Same-day clinical results with turnaround time under 6 hours
+3 more records
Product overview1 text field

Nephrolyx offers a dual-product portfolio centered on kidney function diagnostics. The core clinical product is Nephrolyx IVDx, which combines an IVD kit with the GFRx software module for measured Glomerular Filtration Rate (mGFR) determination using iohexol plasma clearance in clinical routine settings. For research applications, the company provides DNPx (Digital Nephrology Platform), a software platform that calculates GFR using pharmacokinetic algorithms with support for multiple and single-sample protocols. The IVDx is designed for laboratories using semi-automatic UHPLC or HPLC processing, while DNPx is positioned for research use only.

Product and service2 records
1Nephrolyx IVDx
CategoryIn Vitro Diagnostic (IVD) Kit + Software
Description

A CE-marked in vitro diagnostic (IVD) kit combined with a digital GFRx software module for measuring Glomerular Filtration Rate (mGFR) using iohexol plasma clearance in clinical routine. Designed for laboratory settings using semi-automatic processing in UHPLC or HPLC devices. The GFRx software module integrates into LIMS systems for automated GFR reporting.

2DNPx (Digital Nephrology Platform)
CategoryResearch Software Platform
Description

A digital research-use platform that calculates Glomerular Filtration Rate (GFR) using pharmacokinetic algorithms from iohexol concentrations obtained through (U)HPLC measurements. Supports both multiple-sample protocols (two-sample minimum) and single-sample protocols. Available for research use only, with a 2-week online demo trial offered.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2013-01-01
Description

12-year research partnership foundational to company creation. Company builds on extensive research in kidney function diagnostics at one of Europe's leading university hospitals. Research background underpins all proprietary technology development.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

MediBeacon is developing transdermal, fluorescent iohexol-based mGFR measurement (TGFR), making it the closest methodological and clinical peer to Nephrolyx in commercializing iohexol gold-standard GFR testing outside the laboratory.

TypeDirect peer
Description

BioPorto commercializes NGAL-based acute kidney injury diagnostics (e.g., The NGAL Test) and other kidney-injury biomarkers, serving overlapping nephrology and clinical-laboratory customers with adjacent renal-diagnostic products.

TypeBroad incumbent
Description

Siemens Healthineers runs a broad clinical-chemistry/immunoassay portfolio (Atellica, ADVIA Centaur) used by the same clinical labs Nephrolyx targets, and could either compete in or provide the platform through which mGFR is ultimately delivered.

TypeBroad incumbent
Description

Roche is the global IVD leader (cobas platforms) serving hospital and reference labs with broad renal-function chemistry menus, making it the principal scale competitor for any routine kidney-function assay adoption.

5Abbott Diagnostics
TypeBroad incumbent
Description

Abbott's diagnostics arm (ARCHITECT, Alinity ci) supplies clinical chemistry assays including renal panels to the same hospital and reference-lab customer base, positioning it as a broad incumbent that could bundle or compete with mGFR assays.

6Beckman Coulter (Danaher)
TypeBroad incumbent
Description

Beckman Coulter offers DxC/AU clinical chemistry platforms widely deployed in routine hospital laboratories, representing both a competing platform route and a potential partnership/distribution channel for kidney-function assays.

TypeBroad incumbent
Description

DiaSorin is a specialty diagnostics player with a strong European footprint in clinical and specialty immunoassays, overlapping with Nephrolyx's nephrology-focused clinical-laboratory channel.

TypeBroad incumbent
Description

As the global dialysis and integrated kidney-care leader, Fresenius Medical Care is a structural buyer/partner candidate for any technology that improves precision of renal-function assessment in CKD and dialysis patients.

TypeBroad incumbent
Description

EUROIMMUN/Revvity operates specialty autoimmune and kidney-disease assay lines across European clinical labs, overlapping with the nephrology diagnostics audience Nephrolyx is approaching.

TypeOthers
Description

Bayer markets iohexol (Omnipaque), the upstream contrast/filtration marker used in Nephrolyx's chemistry, making it a key upstream relationship and potential strategic partner in clinical and research supply.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nephrolyx

Clinical Kidney Function Diagnosticsnephrolyx.com

Nephrolyx GmbH is a Berlin-based diagnostics company that provides CE-marked Nephrolyx IVDx (iohexol IVD kit plus GFRx LIMS-integrated software) and the DNPx research platform for measured Glomerular Filtration Rate (mGFR) kidney function testing, serving clinical laboratories, physicians, hospitals, and pharma/biotech research customers across EMEA.

What Nephrolyx does

Nephrolyx GmbH is a Berlin-based diagnostics company that develops measured Glomerular Filtration Rate (mGFR) testing solutions for kidney function assessment. Its core product, Nephrolyx IVDx, combines a CE-marked in vitro diagnostic (IVD) iohexol-based kit with a digital GFRx software module that integrates into customer Laboratory Information Management Systems (LIMS) and computes mGFR via pharmacokinetic algorithms from (U)HPLC measurement data. The company also offers DNPx, a digital nephrology platform for research use supporting both multi-sample and single-sample protocols. The underlying technology leverages 12 years of research conducted at Charité Universitätsmedizin Berlin and is positioned as a more accurate, cost-effective, and rapid (<6-hour turnaround) alternative to existing mGFR methods such as 99mTc-DTPA and lab-developed tests, as well as biomarker-based estimated GFR (eGFR) approaches.

The company serves clinical laboratories with UHPLC/HPLC capabilities, physicians and nephrologists, hospitals and ambulatory care settings, and pharma/biotech companies conducting kidney research and clinical trials. Revenue is generated through IVD kit sales, software licensing/subscription for the GFRx module and DNPx platform, and professional services or research-collaboration arrangements with pharmaceutical sponsors. Pricing is quote-based and not publicly disclosed; go-to-market is enterprise field sales supported by a 2-week demo trial, with primary marketing channels being the corporate website, LinkedIn, and earned media in German outlets such as Der Tagesspiegel and Adlershof news. Funding to date has come entirely from a non-dilutive ERDF/State of Brandenburg ProFIT grant (NephroAL project); no institutional venture equity is disclosed. Leadership is led by Managing Director Dr. Markus Riester, with operations across Berlin-Adlershof and Wildau, Germany.

Geographically, Nephrolyx is CE-marked for the European market and explicitly not available for clinical diagnostic use in the United States, with EMEA as the disclosed served market. The company has 1-10 employees and operates as an independent, founder-driven German private limited liability company.

Nephrolyx firmographics

Firmographics
Name
Nephrolyx
Legal name
Nephrolyx GmbH
Website
https://nephrolyx.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Short description
Nephrolyx GmbH is a Berlin-based diagnostics company that provides CE-marked Nephrolyx IVDx (iohexol IVD kit plus GFRx LIMS-integrated software) and the DNPx research platform for measured Glomerular Filtration Rate (mGFR) kidney function testing, serving clinical laboratories, physicians, hospitals, and pharma/biotech research customers across EMEA.
Ownership category
akta.pro rank

Nephrolyx industry classification

Industry
Product category
Clinical Kidney Function Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAHAKAJ
Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status)

Keywords

  • Kidney function diagnostics
  • Glomerular filtration rate
  • Iohexol plasma clearance
  • In vitro diagnostics
  • Nephrology software platform

Where Nephrolyx is headquartered

Location

Headquarters

HQ city
Berlin
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

Nephrolyx business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. IVD Kit Sales: Sale of IVD kits for clinical kidney function diagnostics. Nephrolyx IVDx combines an IVD kit with a digital software module.
  2. Software Licensing (GFRx/DNPx): Digital GFRx software module for clinical use integrated into LIMS systems, and DNPx digital platform for research use. Software modules likely sold through licensing or subscription model.
  3. Pharma/Biotech Research Support: Supporting pharma and biotech companies in kidney research and clinical trials, likely through service or licensing arrangements.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise/Laboratory pricing - quote-based

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Nephrolyx product offering

Product offering

Core offering

Nephrolyx develops and sells the Nephrolyx IVDx, a CE-marked in vitro diagnostic (IVD) kit combined with a digital GFRx software module for measuring Glomerular Filtration Rate (mGFR) using iohexol-plasma-clearance in clinical routine. The software integrates into laboratory LIMS systems and is designed for semi-automatic processing on UHPLC/HPLC devices. For research use, Nephrolyx offers the DNPx Digital Nephrology Platform, which calculates mGFR via pharmacokinetic algorithms from iohexol concentrations obtained through (U)HPLC measurements.

Product overview

Nephrolyx offers a dual-product portfolio centered on kidney function diagnostics. The core clinical product is Nephrolyx IVDx, which combines an IVD kit with the GFRx software module for measured Glomerular Filtration Rate (mGFR) determination using iohexol plasma clearance in clinical routine settings. For research applications, the company provides DNPx (Digital Nephrology Platform), a software platform that calculates GFR using pharmacokinetic algorithms with support for multiple and single-sample protocols. The IVDx is designed for laboratories using semi-automatic UHPLC or HPLC processing, while DNPx is positioned for research use only.

Differentiator

Problem solved

Functional benefit

Products and services

  • Nephrolyx IVDx A CE-marked in vitro diagnostic (IVD) kit combined with a digital GFRx software module for measuring Glomerular Filtration Rate (mGFR) using iohexol plasma clearance in clinical routine. Designed for laboratory settings using semi-automatic processing in UHPLC or HPLC devices. The GFRx software module integrates into LIMS systems for automated GFR reporting.
  • DNPx (Digital Nephrology Platform) A digital research-use platform that calculates Glomerular Filtration Rate (GFR) using pharmacokinetic algorithms from iohexol concentrations obtained through (U)HPLC measurements. Supports both multiple-sample protocols (two-sample minimum) and single-sample protocols. Available for research use only, with a 2-week online demo trial offered.

Quantifiable outcome

  • Same-day clinical results with turnaround time under 6 hours
  • +3 more outcomes

Companies that use Nephrolyx

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Nephrolyx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Nephrolyx partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Charité Universitätsmedizin BerlincoreStrategic or Co-development Partner · 1 January 201312-year research partnership foundational to company creation. Company builds on extensive research in kidney function diagnostics at one of Europe's leading university hospitals. Research background underpins all proprietary technology development.

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Nephrolyx competitors and assessment

Company assessment

Direct peers

  • MediBeacon: MediBeacon is developing transdermal, fluorescent iohexol-based mGFR measurement (TGFR), making it the closest methodological and clinical peer to Nephrolyx in commercializing iohexol gold-standard GFR testing outside the laboratory.
  • BioPorto Diagnostics: BioPorto commercializes NGAL-based acute kidney injury diagnostics (e.g., The NGAL Test) and other kidney-injury biomarkers, serving overlapping nephrology and clinical-laboratory customers with adjacent renal-diagnostic products.

Broad incumbents

  • Siemens Healthineers: Siemens Healthineers runs a broad clinical-chemistry/immunoassay portfolio (Atellica, ADVIA Centaur) used by the same clinical labs Nephrolyx targets, and could either compete in or provide the platform through which mGFR is ultimately delivered.
  • Roche Diagnostics: Roche is the global IVD leader (cobas platforms) serving hospital and reference labs with broad renal-function chemistry menus, making it the principal scale competitor for any routine kidney-function assay adoption.
  • Abbott Diagnostics: Abbott's diagnostics arm (ARCHITECT, Alinity ci) supplies clinical chemistry assays including renal panels to the same hospital and reference-lab customer base, positioning it as a broad incumbent that could bundle or compete with mGFR assays.
  • Beckman Coulter (Danaher): Beckman Coulter offers DxC/AU clinical chemistry platforms widely deployed in routine hospital laboratories, representing both a competing platform route and a potential partnership/distribution channel for kidney-function assays.
  • DiaSorin: DiaSorin is a specialty diagnostics player with a strong European footprint in clinical and specialty immunoassays, overlapping with Nephrolyx's nephrology-focused clinical-laboratory channel.
  • Fresenius Medical Care: As the global dialysis and integrated kidney-care leader, Fresenius Medical Care is a structural buyer/partner candidate for any technology that improves precision of renal-function assessment in CKD and dialysis patients.
  • EUROIMMUN (PerkinElmer/Revvity): EUROIMMUN/Revvity operates specialty autoimmune and kidney-disease assay lines across European clinical labs, overlapping with the nephrology diagnostics audience Nephrolyx is approaching.

Others

  • Bayer (Radiology / Contrast Media): Bayer markets iohexol (Omnipaque), the upstream contrast/filtration marker used in Nephrolyx's chemistry, making it a key upstream relationship and potential strategic partner in clinical and research supply.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Nephrolyx social profiles

Digital presence

Nephrolyx compliance and trust

Trust signal

Compliance1 record

Nephrolyx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nephrolyx leadership team

Management profile

Number of profiles

Profiles1 record

Nephrolyx funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nephrolyx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nephrolyx

What does Nephrolyx do?

Nephrolyx develops and sells the Nephrolyx IVDx, a CE-marked in vitro diagnostic (IVD) kit combined with a digital GFRx software module for measuring Glomerular Filtration Rate (mGFR) using iohexol-plasma-clearance in clinical routine. The software integrates into laboratory LIMS systems and is designed for semi-automatic processing on UHPLC/HPLC devices. For research use, Nephrolyx offers the DNPx Digital Nephrology Platform, which calculates mGFR via pharmacokinetic algorithms from iohexol concentrations obtained through (U)HPLC measurements.

Is Nephrolyx a public or private company?

Nephrolyx is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Nephrolyx founded?

Nephrolyx was founded in 2012. It employs 1 to 10 people.

Where is Nephrolyx based?

Nephrolyx is headquartered in Berlin, Germany, in the Europe region.

How does Nephrolyx make money?

Three revenue lines are on record. IVD Kit Sales are the primary driver. The others are software Licensing (GFRx/DNPx) and pharma/Biotech Research Support.

Who are Nephrolyx's main competitors?

Direct peers on record are MediBeacon and BioPorto Diagnostics. Broad incumbents are Siemens Healthineers, Roche Diagnostics, Abbott Diagnostics, Beckman Coulter (Danaher), DiaSorin, Fresenius Medical Care and EUROIMMUN (PerkinElmer/Revvity). Bayer (Radiology / Contrast Media) is listed as an others.

Does Nephrolyx have an API?

No public API is recorded for Nephrolyx.

What industry is Nephrolyx in?

Nephrolyx's product category is Clinical Kidney Function Diagnostics. Its primary akta.pro industry code is HLAHAKAJ, Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales